**International Journal of Healthcare Sciences** ISSN 2348-5728 (Online)
Vol. 5, Issue 1, pp: (354-361), Month: April - September 2017, Available at: www.researchpublish.com

# Early Screening for Rheumatoid Arthritis, And Treatment Outcomes, Review

[1]Faisal Rabeea Alanazi, [2]Mohammed Nafy Alruwaily, [3]Mohammed Zhafer Alqarni, [4]Abdullah Sami Bunaian, [5]Nasser Khalid Alotaibi, [6]Abdulaziz Mohammed Alessa, [7]Mansour Abdullah Alnaim

***Abstract:*** **The aim of this review study was to discuss and highlighting the most important aspects on Rheumatoid arthritis (RA), mainly discussing the diagnosis and therapeutics management, also to review the pathogenesis and causes behind the RA. We conducted detailed search reviewing articles related to Rheumatoid arthritis (RA), using electronic databases; Medline/PubMed, Embase, and Google scholar. Search strategy used following terms through PubMed; "Rheumatoid arthritis" "diagnosis," "screening," and "treatment". We applied restriction to our search, for only these studies published up to May,2017 with English language, and involving human subjects. RA, a systemic autoimmune disease involving the joints and also various other organs, is associated with death, disability, and also pain. Growing evidence recommends that very early recognition and therapy of RA brings about boosted results and even boosted rates of drug-free remission. The optimal time to treat and recognize RA is unknown; nonetheless, less than 3-- 6 months of symptoms of IA appears to be a good time duration to target for initiation of DMARD therapy, although this target may be difficult to get to as a result of several factors that could affect very early medical diagnosis of RA. The 2010 ACR/EULAR classification requirements show up to recognize RA earlier compared to the 1987 standards, although the performance of these brand-new requirements in leading to improved end results in RA needs further examination.**

***Keywords:*** **Rheumatoid arthritis (RA), ACR/EULAR classification requirements.**

## 1. INTRODUCTION

Rheumatoid arthritis (RA) is an inflammatory rheumatic disease with progressive course impacting articular and extra-articular structures resulting in death, special needs and pain [(1)]. Relentless inflammation causes erosive joint damage and functional disability in the huge bulk of patients [(2, 3)]. The start of disease is not similar in all patients however differs in regard to type, number, and the pattern of joint participation. The course of disease may be likewise various according to the existence or absence of a number of variables including genetic background, frequency of swollen joints, autoantibody in the serum and the severity of inflammatory procedure [(4, 5)]. The detailed public health of RA is suggestive of a genetic result. The occurrence of RA is relatively continuous with a frequency of between 0.5 and 1.0%, a frequency that has been reported from a number of European and North-American populations [(6,7,8,9,10,11,12,13,14)] (**Fig. 1**).

The precise reason for RA is unknown. The leading hypothesis for this (and most other autoimmune conditions) is that RA is the outcome of an environmental exposure or "trigger" in a genetically vulnerable individual [(15)]. Some environmental factors connected to gender have emerged. Women who actively take contraceptive pills have a lower occurrence of RA compared with ladies who never ever took contraceptive pills or those who formerly took contraceptive pills [(16)]. Both female subfertility and the instant postpartum period after a very first pregnancy (specifically when breastfeeding) appear to increase the risk of RA.10 Other potential environmental triggers consist of viral infections, such as those of Epstein-Barr virus, parvovirus, and bacterial infections with organisms such as Proteus and Mycoplasma. Heat-shock proteins and other stress factors (eg, hypothalamic-pituitaryadrenal changes during adverse or distressing life occasions) affect immune guideline and cytokine production [(17)].

Accurate diagnosis of early RA starts with clear definitions of RA, as well as early. There is considerable irregularity in the literature regarding the time frame specifying early RA [18]. Previous intervention research studies in early RA have included early RA as disease period from 3 months to 3 years; nevertheless, with the knowledge of improved outcomes with earlier treatment in RA, it becomes clear that a shorter time period for category of early RA is medically substantial. Due to the wide range of meanings of early RA provided in the literature, it is tough to identify the specific timespan that specifies early RA. It is now usually accepted that early RA is the onset of symptoms of joint (usually polyarticular) pain, tightness, or swelling within the past 3 months [19,20]. The prognosis of RA is impacted by the severity of the disease and the effectiveness of treatment [21]. Scientific remissions, defined as the lack of considerable signs and symptoms of inflammation with or without extra treatment, happens in 20% or less of patients. In contrast, remission or achievement of low disease activity (LDA), normally with continuing treatment, might be achieved in approximately 75% of patients [21]. Despite accomplishment of LDA, radiographic proof of the progression of joint damage and synovitis through monitoring of MRI or ultrasound outcomes have been noted [21]. More than one-third of patients with medical remission exhibition indications of synovitis on ultrasound [22].




**Figure 1: Prevalence of rheumatoid arthritis in various populations. Data from [6,7,8,9,10,11,12,13,14]**

**The aim of this review study was to discuss and highlighting the most important aspects on Rheumatoid arthritis (RA), mainly discussing the diagnosis and therapeutics management, also to review the pathogenesis and causes behind the RA.**

## 2. METHODOLOGY

We conducted detailed search reviewing articles related to Rheumatoid arthritis (RA), using electronic databases; Medline/PubMed, Embase, and Google scholar. Search strategy used following terms through PubMed; "Rheumatoid arthritis" "diagnosis," "screening," and "treatment". We applied restriction to our search, for only these studies published up to May,2017 with English language, and involving human subjects

## 3. DISCUSSION

- **Etiology and risk factors:**

Rheumatoid arthritis includes a complicated interplay among genotype, environmental triggers, and chance. Twin studies implicate genetic consider rheumatoid arthritis, with concordance rates of 15 to 30% among monozygotic twins and 5% amongst dizygotic twins [23]. Genome broad analyses make it clear that immune regulatory factors underlie the disease [24].

The etiology of rheumatoid arthritis is not fully comprehended. Proof indicate a complex interplay between genetic and environmental factors. In monozygotic twins, there is a more than 30 percent concurrence rate for rheumatoid arthritis advancement, and 80 percent of whites with rheumatoid arthritis reveal the HLA-DR1 or -DR4 subtypes. These and other areas of the Major Histocompatibility Complex might provide vulnerability to more serious disease by causing a specific arthrogenic peptide to be provided to CD4+ T cells [25]. Joint damage in rheumatoid arthritis starts with the expansion of synovial macrophages and fibroblasts after a setting off event, transmittable or possibly autoimmune. Lymphocytes penetrate perivascular regions, and endothelial cells proliferate. Neovascularization then takes place. Blood vessels in the

impacted joint ended up being occluded with inflammatory cells or small embolisms. With time, swollen synovial tissue starts to grow irregularly, forming intrusive pannus tissue. Pannus destroys and invades cartilage and bone. Several cytokines, interleukins, proteinases, and development factors are released, causing additional joint damage and the development of systemic complications [25,26].

Female sex, a favorable family history, older age, silicate direct exposure, and smoking are related to an increased risk for developing rheumatoid arthritis [25,27,28]. Intake of more than 3 cups of coffee day-to-day especially decaffeinated coffee also may contribute [29]. High vitamin D consumption, tea intake, and oral contraceptive use are connected with reduced risk [28,29,30]. 3 in 4 ladies with rheumatoid arthritis experience significant enhancement in signs when pregnant, usually with a reoccurrence after delivery [27].

Synovitis happens when leukocytes penetrate the synovial compartment. Leukocyte build-up mainly shows migration rather than local proliferation. Cell migration is made it possible for by endothelial activation in synovial microvessels, which increases the expression of adhesion molecules (consisting of integrins, selectins, and members of the immunoglobulin superfamily) and chemokines. Accordingly, neoangiogenesis, which is induced by local hypoxic conditions and cytokines, and insufficient lymphangiogenesis, which limits cellular egress, are characteristic functions of established and early synovitis [31,32]. These microenvironmental modifications, combined with extensive synovial architectural reorganization and local fibroblast activation, permit the buildup of synovial inflammatory tissue in rheumatoid arthritis (**Fig. 2**) [17].




**Fig. 2: Adaptive and Innate Immune Processes within the Joint in Rheumatoid Arthritis [17].**

**Diagnosis of RA:**

The diagnosis of RA is made clinically based primarily on physical examination findings [17]. The 2 main category requirements are summarized in (**Table 1**) [33,34]. The category requirements published in 1987 by the American College of Rheumatology (ACR), previously the American Rheumatism Association, have been criticized for their focus on recognizing patients with more-established RA disease (ie, those who have currently established chronic erosive disease)

[34]. The 1987 requirements failed to determine patients with early disease, who might acquire the most benefit from offered treatments [33]. Recently, the ACR and European League Against Rheumatism (EULAR) developed a joint working group with the primary goal of developing classification criteria to identify patients previously in the disease process [34]. Just like the 1987 effort, the 2010 category requirements are a means to identify patients for clinical trials, to differentiate patients with synovitis, and to determine the group at greatest risk for developing persistent or erosive RA. The 2010 ACR/EULAR category criteria also produced a schematic for determining certain RA [34]. The very first crucial step towards enhancing the long-lasting prognosis is early verification of the medical diagnosis of RA. The primary sign of RA is joint swelling, and other possible reasons for this swelling must be left out (**Fig. 3**) [35].

**Table 1: ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) [34]**

| **Points** | **0** | **1** | **2** | **3** | **5** |
|---|---|---|---|---|---|
| **Swollen/painful joints** | ≤ 1 (medium to) large joint | 2–10 (medium to) large joints | 1–3 small joints | 4–10 small joints | ≥ 11 including small joints |
| **Serology** RF and ACPA | Negative | | One or both weakly positive | One or both strongly positive | |
| **Acute phase** CRP und ESR | Normal | One or both elevated | | | |
| **Duration of symptoms** | <6 weeks | ≥ 6 weeks | | | |




**Fig.3: Diagnostic algorithm for investigation of patients with joint swelling [35]**

Recognition of RA at preliminary presentation as well as therapy at earlier stage can impact disease course, stop the growth of joint erosions or hamper progression of abrasive disease [33]. Early diagnosis as well as treatment might impact disease outcomes also to a remission state [34,35]. Identifying very early RA from non-RA at the start of disease is not uncomplicated yet there is constraint in using the American College of Rheumatology revised criteria (ACR requirements) for early diagnosis. Since due to insufficient scientific or laboratory proofs at beginning of arthritis, this requirements is not delicate enough to determine early RA [34].

In a research study of Frech cohort, only 50.9% of RA completely satisfied 1987 ACR modified standards for medical diagnosis of RA in 1 year [35]. In the absence of treatment inflammation will lead to articular problems and bone disintegration particularly within the very first two years of disease onset [35]. Relating to the present concept of "window of chance", very early medical diagnosis of RA is crucial for initiation of treatment, or else, disease will certainly advance to more severe types calling for a lot more hostile treatment [35].

**Treatment of RA and outcomes:**

Based upon new developed requirements, patients with at the very least one involved joint may call for DMARD treatment in respect to other elements of requirements. RA disease could be thought about a potentially curable condition throughout the evolutionary procedure (from inflammatory joint inflammation to well-known problem) and also the disease program might be transformed by very early ideal hostile therapy [36]. Current expertise and also availability of highly efficient DMARDs or organic treatments urge the objective of treatment being changed to attain remission as opposed to control of inflammation [37]. Earlier identificatiin of high risk people and also an extremely early use of reliable DMARDs is a key point in patients in jeopardy of developing relentless abrasive joint inflammation [38]. On the other hand, delay in beginning treatment with DMARDs was shown to impact long-term outcome substantially [39]. A significant proportion of UA patients are really patients with RA in a really early phase therefore it is necessary to identify UA patients that will certainly develop RA and also treat them as early as feasible [40].

In one research, very early treatment with 3 DMADRs for two years were compared with one DMARDs for 2 years The respective remission rates were 40% as well as 18% after 2 years and also 28%, 22% after 5 years. This study demonstrated that combination treatment with 3 drugs for the initial 2 years limited the peripheral joint damages for a minimum of 5 years [41]. Mix therapy can be extremely reliable especially in patients with early RA. Initial mix treatment puts in greater defense for joint damage and offers earlier scientific enhancements [42]. Mix therapy utilizing biological representatives (infliximab, adalimumab) with methotrexate or biological therapy alone may induce remission in lots of patients with very early RA. Combination therapy should be thought about in patients that have risk factors such as high degree of anti-CCP, RF, joint erosion in radiographs as well as those who have actually shared epitope [43]. Arise from previous research studies suggest that treating high risk patients might slow the progression from very early inflammatory joint inflammation to precise RA and inhibit the progression of joint damages [43]. Combination treatment could avoid radiographic progression even in patients with risk factors such as RF or anti-CCP whereas; monotherapy may be inadequate [44].

**Steroids for administration of RA:**

Administration of steroid in combination with DMARDs or with biological treatments in very early RA could induce a higher rate of remission, control of radiological progression compared to DMARD monotherapy. This program provides far better end result and also ought to be taken into consideration in all patients [37,43]. Systemic glucocorticoids are additionally efficient in the short-term alleviation of pain and also swelling, and also as a result may be considered for these objectives however mostly as a temporary therapy [44].

## 4. CONCLUSION

RA, a systemic autoimmune disease involving the joints and also various other organs, is associated with death, disability, and also pain. Growing evidence recommends that very early recognition and therapy of RA brings about boosted results and even boosted rates of drug-free remission. The optimal time to treat and recognize RA is unknown; nonetheless, less than 3-- 6 months of symptoms of IA appears to be a good time duration to target for initiation of DMARD therapy, although this target may be difficult to get to as a result of several factors that could affect very early medical diagnosis of RA. The 2010 ACR/EULAR classification requirements show up to recognize RA earlier compared to the 1987 standards, although the performance of these brand-new requirements in leading to improved end results in RA needs further examination.

## REFERENCES

[1] Birch JT Jr, Bhattacharya S. Emerging trends in diagnosis and treatment of rheumatoid arthritis. Prim Care. 2010;37:779–92.

[2] El Miedany Y, Youssef S, Mehanna AN, El Gaafary M. Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. Joint Bone Spine. 2008;75:155–62.

[3] Combe B. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23:59–69.

[4] Gossec L, Combescure C, Rincheval N, et al. Relative Clinical influence of Clinical, Laboratory, and Radiological Investigations in Early Arthritis on the Diagnosis of Rheumatoid Arthritis. Data from the French Early Arthritis Cohort ESPOIR. J Rheumatol. 2010;37:2486–92.

[5] Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006;55:864–72.

[6] Carmona L, Villaverde V, Hernandez-Garcia C, Ballina J, Gabriel R, Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology. 2002;41:88–95. doi: 10.1093/rheumatology/41.1.88.

[7] Riise T, Jacobsen BK, Gran JT. Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. J Rheumatol. 2000;27:1386–1389.

[8] Aho K, Kaipiainen-Seppanen O, Heliovaara M, Klaukka T. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum. 1998;27:325–334.

[9] Cimmino MA, Parisi M, Moggiana G, Mela GS, Accardo S. Prevalence of rheumatoid arthritis in Italy: the Chiavari study. Ann Rheum Dis. 1998;57:315–318.

[10] Kvien TK, Glennas A, Knudsrod OG, Smedstad LM, Mowinckel P, Forre O. The prevalence and severity of rheumatoid arthritis in Oslo: results from a county register and a population survey. Scand J Rheumatol. 1997;26:412–418.

[11] Power D, Codd M, Ivers L, Sant S, Barry M. Prevalence of rheumatoid arthritis in Dublin, Ireland: a population based survey. Ir J Med Sci. 1999;168:197–200.

[12] Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A, Guillemin F, Youinou P, Le Goff P. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. J Rheumatol. 1999;26:2622–2627.

[13] Simonsson M, Bergman S, Jacobsson LT, Petersson IF, Svensson B. The prevalence of rheumatoid arthritis in Sweden. Scand J Rheumatol. 1999;28:340–343. doi: 10.1080/03009749950155319.

[14] Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum. 1999;42:415–420. doi: 10.1002/1529-0131(199904)42:3<415::AID-ANR4>3.0.CO;2-Z.

[15] Gibofsky A, Winchester RJ, Patarroyo M, Fotino M, Kunkel HG. Disease associations of the Ia-like human alloantigens: contrasting patterns in rheumatoid arthritis and systemic lupus erythematosus. J Exp Med. 1978;148(6):1728-1732.

[16] Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(suppl 3):S265-S272.

[17] McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.

[18] van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007;56:433–40.

[19] Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Attitudes to early rheumatoid arthritis: changing patterns: results of a survey. Ann Rheum Dis. 2004;63:1269–75.

[20] Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–39. This article provides an expert opinion based on a literature review regarding the management of RA.

[21] Machold KP. Prevention and cure of rheumatoid arthritis: is it possible? Best Prac Res Clin Rheumatol. 2010;24(3):353-361.

[22] Zufferey P, Möller B, Brulhart L, Tamborrini G, Scherer A, Ziswiler HR. Persistence of ultrasound synovitis in the patients fulfilling the DAS and/or the new ACR/EULAR RA remission definitions: results of the SONAR score applied to the patients of the SCQM cohort. Ann Rheum Dis. 2012;71(suppl 3):149.

[23] MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.

[24] Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78.

[25] Goldring SR. A 55-year-old woman with rheumatoid arthritis. JAMA. 2000;283:524–31.

[26] Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Kelley's Textbook of Rheumatology. 7th ed. Philadelphia: W.B. Saunders, 2005:996–1042.

[27] Harris ED. Clinical features of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Kelley's Textbook of rheumatology. 7th ed. Philadelphia: WB Saunders, 2005:1043–78.

[28] Kuder SA, Peshimam AZ, Agraharam S. Environmental risk factors for rheumatoid arthritis. Rev Environ Health. 2002;17:307–15.

[29] Mikuls TR, Cerhan JR, Criswell LA, Merlino L, Mudano AS, Burma M, et al. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 2002;46:83–91.

[30] Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 2004;50:72–7.

[31] Szekanecz Z, Pakozdi A, Szentpetery A, Besenyei T, Koch AE. Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci (Elite Ed) 2009;1:44-51.

[32] Polzer K, Baeten D, Soleiman A, et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann Rheum Dis 2008;67:1610-6.

[33] Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.

[34] Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.

[35] Schneider M, Lelgemann M, Abholz HH, et al. http://dgrh.de/leitlinien.html. Heidelberg: Springer Verlag; 2011. Management der frühen rheumatoiden Arthritis.

[36] Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. Curr Opin Rheumatol. 2009;21:118–23.

[37] Cush JJ. Early rheumatoid arthritis is there a window of opportunity? J Rheumatol. 2007;80:1–7.

[38] Combe B. Suppl Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007;21:27–42.

[39] . Graudal N. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol Suppl. 2004;118:1–38.

[40] Verpoort KN, van Dongen H, Allaart CF, et al. Undifferentiated arthritis--disease course assessed in several inception cohorts. Clin Exp Rheumatol. 2004;22:S12–7.

[41] Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072–81.

[42] Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146:406–15.

[43] Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol. 2008;66:173–8.

[44] de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum. 2008;58:1293–8.